3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
35
Carcinoma, Non-Small-Cell Lung
32
Colorectal Neoplasms
19
Esophageal Squamous Cell Carcinoma
18
Stomach Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
16
Rectal Neoplasms
11
Cholangiocarcinoma
11
Head and Neck Neoplasms
10
Small Cell Lung Carcinoma
9
Lung Neoplasms
9
Esophageal Neoplasms
9
Triple Negative Breast Neoplasms
8
Uterine Cervical Neoplasms
7
Nasopharyngeal Carcinoma
7
Urinary Bladder Neoplasms
6
Recurrence
6
Pancreatic Neoplasms
6
Neoplasms
6
Colonic Neoplasms
6
Melanoma
5
Hodgkin Disease
5
Biliary Tract Neoplasms
4
Adenocarcinoma of Lung
4
Sarcoma
3
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
NSCLC
3
Locally Advanced Rectal Cancer
3
Liver Neoplasms
3
Interventions
pembrolizumab
3
atezolizumab
2
Sugammadex
2
Saline Solution
2
Paclitaxel
2
Neostigmine
2
Gemcitabine
2
Cetuximab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
poly ICLC
1
lenvatinib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
delta 24-sterol reductase
1
daratumumab
1
cabozantinib
1
abemaciclib
1
Zoledronic Acid
1
Water
1
Valproic Acid
1
Urinary Diversion
1
Ultrasonography
1
Trastuzumab
1
Tomography, Optical Coherence
1
Tissue Banks
1
Therapeutics
1
Testosterone Propionate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urologic Neoplasms
×
tislelizumab
×
Clear all
NCT04922047
2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2
Unknown
6 enrolled